Abstract:The orphan nuclear receptor NR4A1 is expressed in tumors from rhabdomyosarcoma (RMS) patients and Rh30 and RD RMS cell lines, and we used RNA interference (RNAi) to investigate the role of this receptor in RMS cells. Knockdown of NR4A1 in Rh30 cells decreased cell proliferation, induced Annexin V staining and induced polyADPribose polymerase (PARP) cleavage and these results were similar to those observed in other solid tumors. Previous studies show that NR4A1 regulates expression of growth promoting/pro-survival genes with GC-rich promoters, activates mTOR through suppression of p53, and maintains low oxidative stress by regulating expression of isocitrate dehydrogenase 1 (IDH1) and thioredoxin domain containing 5 (TXNDC5). Results of RNAi studies demonstrated that NR4A1 also regulates these pathways and associated genes in RMS cells and thereby exhibits pro-oncogenic activity. 1,1-Bis(3-indolyl)-1-(p-substituted phenyl)methane (C-DIM) analogs containing p-hydroxyl (DIM-C-pPhOH) and p-carboxymethyl (DIM-C-pPhCO2Me) substituents are NR4A1 ligands that decreased NR4A1-dependent transactivation in RMS cells and inhibited RMS cell and tumor growth and induced apoptosis. Moreover, the effects of NR4A1 knockdown and the C-DIM/NR4A1 antagonists were comparable as inhibitors of NR4A1-dependent genes/pathways. Both NR4A1 knockdown and treatment with DIM-C-pPhOH and DIM-C-pPhCO2Me also induced ROS which activated stress genes and induced sestrin 2 which activated AMPK and inhibited mTOR in the mutant p53 RMS cells. Since NR4A1 regulates several growth-promoting/pro-survival pathways in RMS, the C-DIM/NR4A1 antagonists represent a novel mechanism-based approach for treating this disease alone or in combination and thereby reducing the adverse effects of current cytotoxic therapies.

HES4 controls redox balance and supports pyrimidine synthesis and tumor growth

RNAi screens identify HES4 as a regulator of redox balance supporting pyrimidine synthesis and tumor growth

The NADPH oxidase NOX4 regulates redox and metabolic homeostasis preventing HCC progression

Nek4 Regulates Entry into Replicative Senescence and the Response to DNA Damage in Human Fibroblasts.

Identification of pyrimidine derivatives as hSMG-1 inhibitors.

NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4

The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response

Dysregulation of hexosamine biosynthetic pathway wiring metabolic signaling circuits in cancer

Inhibition of NR4A1 Promotes ROS Accumulation and IL24-Dependent Growth Arrest in Rhabdomyosarcoma

Redox metabolism maintains the leukemogenic capacity and drug resistance of AML cells

Therapeutic potential of NR4A1 in cancer: Focus on metabolism

A single H/ACA small nucleolar RNA mediates tumor suppression downstream of oncogenic RAS

Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition

NAD(P)HX epimerase downregulation promotes tumor progression through ROS/HIF‐1α signaling in hepatocellular carcinoma

Cellular redox sensor HSCARG negatively regulates the translesion synthesis pathway and exacerbates mammary tumorigenesis.

Is Nucleoredoxin a Master Regulator of Cellular Redox Homeostasis? Its Implication in Different Pathologies

Nuclear receptor 4A1 (NR4A1) as a drug target for treating rhabdomyosarcoma (RMS)

Human NQO1 as a Selective Target for Anticancer Therapeutics and Tumor Imaging

MTHFD2-mediated redox homeostasis promotes gastric cancer progression under hypoxic conditions

Regulation of redox homeostasis through DNA/RNA methylation and post-translational modifications in cancer progression

A Novel Reductase‐Independent Role of Nuclear Ribonucleotide Reductase